Delivery Order SPE2DB20D2104-SPE2DB25FMPRY

Award Date 4/29/25
Potential Completion Date 4/30/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,433.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of the medication XELJANZ XR 11 MG TABLET UU 30S. The contract has an ultimate completion date of April 18, 2025 and is a firm fixed-price agreement. Amerisourcebergen Drug Corp is the prime contractor, and there is no set-aside designation indicated. This award is part of a...
This federal contract award, valued at $7,511.62, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of December 5, 2024 and is a Firm Fixed Price Delivery Order with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award, valued at $6,030.88, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, and is a firm fixed-price delivery order with a period of performance through March 31, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $19,811.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of XELJANZ XR 11 MG TABLET, a prescription medication, with a performance period extending through April 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XELJANZ XR 11 MG TABLET prescription medication. The firm-fixed-price delivery order, valued at $39,154.40, has a completion date of February 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This federal contract award, valued at $26,447.95, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, and it has an ultimate completion date of January 22, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not associated with a set-aside designation, indicating...
This federal contract award is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of XELJANZ XR 11 MG TABLET in support of military healthcare programs. The contract has a firm fixed price, with a ceiling value of $86,441.76, and an ultimate completion date of June 18, 2024. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award, valued at $13,328.88, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for XELJANZ XR 11 MG TABLET UU 30S, with an ultimate completion date of July 25, 2024. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $12,105.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of XELJANZ XR 11 MG TABLET, a pharmaceutical product, with a performance period extending through April 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) vehicle, designated as SPE2DX, which has a total potential value of...
This federal contract award, valued at $35,613.65, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the pharmaceutical product "XELJANZ XR 11 MG TABLET UU 30S". AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMPRY
    Delivery Order

This federal contract award, valued at $3,118.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of XELJANZ XR 11 MG TABLET UU 30S. The contract is a firm fixed-price delivery order with an ultimate completion date of April 30, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This contract award is not designated as a set-aside and allows Amerisourcebergen Drug Corp to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.

Generated 7/29/25, 9:49 AM